Category: Peptide Q&A

Have any long-term studies assessed the risk of metabolic rebound or compensatory hyperphagia after Adipotide treatment?

Are there differences in efficacy and safety between single-dose versus repeated-dose administration of Adipotide in animal studies?

What are the limitations of the existing preclinical evidence for Adipotide, particularly regarding translation to human physiology?

What are the primary safety concerns associated with Adipotide, particularly regarding off-target effects on non-adipose endothelial cells?

How does Adipotide compare to other anti-angiogenic therapies in terms of specificity for adipose vasculature?

What evidence exists on hepatotoxicity, nephrotoxicity, or immunogenicity following Adipotide administration in animal models?

What ethical considerations arise from using a compound that induces selective fat cell death, and how might this influence regulatory approval?

What is the current level of clinical evidence supporting Adipotide’s efficacy in humans, and why has it not advanced to widespread clinical use?

How does the expression of prohibitin vary across different adipose depots, and does this influence Adipotide’s efficacy in subcutaneous vs. visceral fa

What is the molecular mechanism by which Adipotide induces selective apoptosis in adipose tissue, and how does its targeting of endothelial cells in adi